#1 Clinical Trials Search in Europe

Ociperlimab

Ociperlimab is an investigational immunotherapy drug being studied in various clinical trials for the treatment of different types of cancer. This article summarizes key information about ongoing clinical trials using Ociperlimab, including its potential benefits, safety profile, and combinations with other therapies. The trials aim to evaluate Ociperlimab’s efficacy in improving outcomes for patients with lung cancer, breast cancer, lymphoma, and other advanced cancers.

Table of Contents

What is Ociperlimab?

Ociperlimab, also known as BGB-A1217 or WCD118, is a new type of cancer drug that is currently being studied in clinical trials[1][2]. It belongs to a class of medications called immunotherapy, which helps your body’s immune system fight cancer. Ociperlimab is not yet approved for general use, but researchers are testing it to see how well it works and how safe it is for patients with various types of cancer.

How Does Ociperlimab Work?

Ociperlimab is a type of drug called an anti-TIGIT antibody. TIGIT is a protein found on some immune cells that can prevent them from attacking cancer cells. By blocking TIGIT, ociperlimab helps to “take the brakes off” the immune system, allowing it to recognize and fight cancer more effectively[3].

In many clinical trials, ociperlimab is being tested in combination with another immunotherapy drug called tislelizumab (also known as BGB-A317 or Tevimbra). Tislelizumab is an anti-PD-1 antibody, which works in a similar way to ociperlimab but targets a different protein called PD-1. By combining these two drugs, researchers hope to enhance the immune system’s ability to fight cancer[4].

What Cancers Does Ociperlimab Treat?

Ociperlimab is being studied for several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Several trials are testing ociperlimab in patients with advanced or metastatic NSCLC[3][4].
  • Small cell lung cancer (SCLC): A less common but aggressive type of lung cancer[5].
  • Cervical cancer: Cancer that starts in the cervix, which is the lower part of the uterus[1].
  • Esophageal cancer: Cancer of the tube that connects the throat to the stomach[2].
  • Hepatocellular carcinoma: The most common type of liver cancer[6].
  • Diffuse large B-cell lymphoma: A type of blood cancer that affects white blood cells[7].
  • Triple-negative breast cancer: An aggressive type of breast cancer that is difficult to treat[8].

Clinical Trials and Research

Ociperlimab is being studied in various clinical trials, which are research studies that test how well new medical approaches work in people. These trials are looking at different aspects of the drug, including:

  • Efficacy: How well the drug works in treating different types of cancer. Researchers measure this by looking at things like how many patients respond to the treatment, how long the response lasts, and how long patients live without their cancer getting worse[3].
  • Safety: What side effects the drug might cause and how often they occur[9].
  • Dosing: Finding the right amount of the drug to give and how often to give it[1].
  • Combinations: Testing ociperlimab with other cancer treatments, such as other immunotherapy drugs, chemotherapy, or radiation therapy[10].

Side Effects and Safety

As with any medication, ociperlimab can cause side effects. Because the drug is still in clinical trials, researchers are carefully monitoring patients for any adverse reactions. Common side effects of immunotherapy drugs like ociperlimab can include:

  • Fatigue
  • Skin rashes or itching
  • Diarrhea
  • Nausea
  • Fever

More serious side effects can occur if the immune system becomes overactive and attacks healthy tissues. These are called immune-related adverse events (irAEs) and can affect various parts of the body. Researchers are closely monitoring for these effects in clinical trials[9].

Future Prospects

Ociperlimab is still in the early stages of research, but it shows promise for treating several types of cancer. If the clinical trials are successful, it could become an important new option for cancer patients, especially those who don’t respond well to existing treatments.

Researchers are particularly excited about combining ociperlimab with other immunotherapy drugs like tislelizumab. This approach, called combination immunotherapy, might be more effective than using single drugs alone[8].

It’s important to note that while the results so far are encouraging, more research is needed before ociperlimab can be approved for general use. Patients interested in this treatment should talk to their doctors about whether participating in a clinical trial might be right for them.

Trial Identifier Cancer Type Phase Treatment Combination Primary Outcome
NCT04693234 Cervical Cancer 2 Ociperlimab + Tislelizumab Objective Response Rate
NCT04948697 Hepatocellular Carcinoma 2 Ociperlimab + Tislelizumab + BAT1706 Objective Response Rate
NCT05267054 Diffuse Large B-cell Lymphoma 1b/2 Ociperlimab + Tislelizumab or Rituximab Safety and Tolerability
NCT04746924 Non-small Cell Lung Cancer 3 Ociperlimab + Tislelizumab vs Pembrolizumab Overall Survival
NCT04952597 Small Cell Lung Cancer 2 Ociperlimab + Tislelizumab + Chemoradiotherapy Progression-Free Survival
NCT04866017 Non-small Cell Lung Cancer 3 Ociperlimab + Tislelizumab vs Durvalumab Progression-Free Survival
NCT05014815 Non-small Cell Lung Cancer 2 Ociperlimab + Tislelizumab + Chemotherapy Progression-Free Survival
NCT05577702 Non-small Cell Lung Cancer 2 Ociperlimab + Tislelizumab +/- Chemotherapy Major Pathological Response
NCT05809895 Triple Negative Breast Cancer 2 Ociperlimab + Tislelizumab + Chemotherapy Progression-Free Survival

FAQ

  • What is Ociperlimab? Ociperlimab is an investigational immunotherapy drug that targets the TIGIT protein. It is being studied in clinical trials for the treatment of various types of cancer, often in combination with other immunotherapy drugs or chemotherapy.
  • What types of cancer is Ociperlimab being studied for? Ociperlimab is being investigated for several cancer types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (liver cancer), cervical cancer, and diffuse large B-cell lymphoma (DLBCL).
  • How is Ociperlimab administered in clinical trials? In most trials, Ociperlimab is administered intravenously (through an IV) at a dose of 900 mg every 3 weeks. It is often given in combination with other drugs like Tislelizumab or chemotherapy.
  • What are the main goals of the Ociperlimab clinical trials? The main goals of these trials are to evaluate the safety and efficacy of Ociperlimab, either alone or in combination with other treatments. Researchers are measuring outcomes such as overall survival, progression-free survival, objective response rate, and the incidence of side effects.
  • Are there any known side effects of Ociperlimab? As with all clinical trials, researchers are closely monitoring for side effects. The trials are collecting data on adverse events, including immune-related side effects. However, specific side effect information for Ociperlimab is still being gathered through these ongoing studies.

Ongoing Clinical Trials on Ociperlimab

  • Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

    Recruiting

    1 1 1
    Investigated drugs:
    France Italy Poland

  • Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

Glossary

  • Ociperlimab: An investigational immunotherapy drug that targets the TIGIT protein, being studied for the treatment of various types of cancer.
  • Tislelizumab: An anti-PD-1 monoclonal antibody immunotherapy drug often used in combination with Ociperlimab in clinical trials.
  • TIGIT: T cell immunoreceptor with Ig and ITIM domains, a protein targeted by Ociperlimab to enhance the immune system's ability to fight cancer.
  • PD-L1: Programmed Death-Ligand 1, a protein that helps cancer cells evade the immune system. Some trials select patients based on PD-L1 expression levels.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.
  • Concurrent Chemoradiotherapy (cCRT): A treatment approach that combines chemotherapy and radiation therapy given at the same time.
  • Anti-Drug Antibodies (ADAs): Antibodies produced by the body against a therapeutic drug, which can potentially affect its efficacy or safety.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to perform daily activities, often assessed in cancer clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT04693234
  2. https://clinicaltrials.gov/study/NCT04732494
  3. https://clinicaltrials.eu/trial/study-comparing-ociperlimab-and-tislelizumab-with-pembrolizumab-for-patients-with-advanced-non-small-cell-lung-cancer/
  4. https://clinicaltrials.gov/study/NCT05014815
  5. https://clinicaltrials.gov/study/NCT04952597
  6. https://clinicaltrials.gov/study/NCT04948697
  7. https://clinicaltrials.gov/study/NCT05267054
  8. https://clinicaltrials.gov/study/NCT05809895
  9. https://clinicaltrials.gov/study/NCT04866017
  10. https://clinicaltrials.gov/study/NCT05577702